PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21675801-2 2011 Fenofibrate also has a number of nonlipid, pleiotropic effects (e.g. reducing levels of fibrinogen, C-reactive protein, and various pro-inflammatory markers, and improving flow-mediated dilatation) that may contribute to its clinical efficacy, particularly in terms of improving microvascular outcomes. Fenofibrate 0-11 C-reactive protein Homo sapiens 100-118 9655393-8 1998 In hyperlipidaemic patients, fenofibrate treatment decreases the plasma concentrations of interleukin-6, fibrinogen and C-reactive protein. Fenofibrate 29-40 C-reactive protein Homo sapiens 120-138 27539098-0 2016 Hepatotoxic effects of fenofibrate in spontaneously hypertensive rats expressing human C-reactive protein. Fenofibrate 23-34 C-reactive protein Homo sapiens 87-105 21939559-0 2011 Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized controlled trials. Fenofibrate 21-32 C-reactive protein Homo sapiens 36-54 21939559-2 2011 Some but not all randomized and non-randomized clinical trials found significant associations between fenofibrate therapy and CRP but the direction and magnitude of the association varied across studies. Fenofibrate 102-113 C-reactive protein Homo sapiens 126-129 21939559-4 2011 In this study we meta-analyzed randomized clinical trials to determine the short-term effect of fenofibrate on CRP. Fenofibrate 96-107 C-reactive protein Homo sapiens 111-114 21939559-9 2011 Inverse-variance weighted random effects meta-analysis revealed that short-term fenofibrate treatment significantly lowers CRP by 0.58 mg/L (95% CI: 0.36-0.80). Fenofibrate 80-91 C-reactive protein Homo sapiens 123-126 21939559-12 2011 CONCLUSION: Short-term treatment with fenofibrate significantly lowers CRP concentration. Fenofibrate 38-49 C-reactive protein Homo sapiens 71-74 33430859-9 2021 The effective lipid-lowering drugs used were statin alone and statin in association with fenofibrate, which improved both the lipid profile values and the subclinical atherosclerosis markers (ankle-brachial index, carotid intima-media thickness and high-sensitivity C-reactive protein). Fenofibrate 89-100 C-reactive protein Homo sapiens 266-284 27424313-8 2016 When compared with placebo, both combination and fenofibrate significantly decreased apolipoprotein B and non-HDL cholesterol and improved flow-mediated dilation and reduced CRP and fibrinogen (all P<0.05 by ANOVA), however, there were no significant differences between combination and fenofibrate. Fenofibrate 49-60 C-reactive protein Homo sapiens 174-192 27424313-12 2016 Otherwise, combination and fenofibrate significantly reduced apolipoprotein B and non-HDL cholesterol and improved flow-mediated dilation and reduced CRP and fibrinogen to a similar extent. Fenofibrate 27-38 C-reactive protein Homo sapiens 150-153 22935083-4 2013 Compared with placebo, fenofibrate reduced lymphocyte release of interleukin-2, interferon-gamma and tumour necrosis factor-alpha, which was accompanied by a reduction in plasma C-reactive protein levels. Fenofibrate 23-34 C-reactive protein Homo sapiens 178-196 23236325-0 2012 Fenofibrate reduces C-reactive protein levels in hypertriglyceridemic patients with high risks for cardiovascular diseases. Fenofibrate 0-11 C-reactive protein Homo sapiens 20-38 23236325-1 2012 BACKGROUND AND OBJECTIVES: The effects of fenofibrate on C-reactive protein (CRP) are under debate. Fenofibrate 42-53 C-reactive protein Homo sapiens 57-75 23236325-1 2012 BACKGROUND AND OBJECTIVES: The effects of fenofibrate on C-reactive protein (CRP) are under debate. Fenofibrate 42-53 C-reactive protein Homo sapiens 77-80 23236325-2 2012 We investigated the effect of fenofibrate on CRP levels and the variables determining changes. Fenofibrate 30-41 C-reactive protein Homo sapiens 45-48 23236325-5 2012 RESULTS: CRP levels decreased in both the fenofibrate (p=0.003) and comparison (p=0.048) groups. Fenofibrate 42-53 C-reactive protein Homo sapiens 9-12 23236325-7 2012 In patients with a baseline CRP level >=1 mg/L, CRP levels also decreased in both groups (p=0.000 and p=0.001 respectively), however, more in the fenofibrate group than in the comparison group (p=0.025). Fenofibrate 149-160 C-reactive protein Homo sapiens 28-31 23236325-7 2012 In patients with a baseline CRP level >=1 mg/L, CRP levels also decreased in both groups (p=0.000 and p=0.001 respectively), however, more in the fenofibrate group than in the comparison group (p=0.025). Fenofibrate 149-160 C-reactive protein Homo sapiens 51-54 23236325-8 2012 The reduction of CRP was associated with higher baseline CRP levels (r=-0.29, p=0.001), lower body mass index (BMI, r=0.23, p=0.007), and fenofibrate therapy (r=0.19, p=0.025). Fenofibrate 138-149 C-reactive protein Homo sapiens 17-20 23236325-9 2012 CRP levels decreased more in the fenofibrate group than in the comparison group in patients with a BMI <=26 kg/m(2) with borderline significance (-1.21+-1.82 mg/L vs. -0.89+-1.92 mg/L, p=0.097). Fenofibrate 33-44 C-reactive protein Homo sapiens 0-3 23236325-10 2012 In patients with a high density lipoprotein-cholesterol level <40 mg/dL, CRP levels were reduced only in the fenofibrate group (p=0.006). Fenofibrate 112-123 C-reactive protein Homo sapiens 76-79 23236325-11 2012 CONCLUSION: Fenofibrate reduced CRP levels in hypertriglyceridemic patients with high CRP and/or low high density lipoprotein-cholesterol levels and without severe overweight. Fenofibrate 12-23 C-reactive protein Homo sapiens 32-35 23236325-11 2012 CONCLUSION: Fenofibrate reduced CRP levels in hypertriglyceridemic patients with high CRP and/or low high density lipoprotein-cholesterol levels and without severe overweight. Fenofibrate 12-23 C-reactive protein Homo sapiens 86-89 21942979-3 2011 Fenofibrate also has nonlipid, pleiotropic effects (e.g. reducing levels of fibrinogen, C-reactive protein and various pro-inflammatory markers, and improving flow-mediated dilatation) that may contribute to its clinical efficacy, particularly in terms of improving microvascular outcomes. Fenofibrate 0-11 C-reactive protein Homo sapiens 88-106 17522372-5 2007 Micronized fenofibrate also significantly decreased fibrinogen (421 +/- 152 vs 344 +/- 81 mg/dl, p <0.001), hs-CRP (3.3 +/- 3.3 vs 2.1 +/- 1.8 mg/L, p <0.01), and ESR (19.1 +/- 24.8 vs 9.7 +/- 8.7 mm/hr, p <0.01), but did not change proinsulin levels. Fenofibrate 11-22 C-reactive protein Homo sapiens 114-117 19074515-6 2009 Moreover, we discuss the impact of CRP genetic polymorphisms on hsCRP changes in response to 3-week fenofibrate treatment in the genetic intervention of the Genetics of Lipid Lowering Drugs and Diet Network study. Fenofibrate 100-111 C-reactive protein Homo sapiens 35-38 19074515-8 2009 CRP genetic variants further influence differing plasma hsCRP response after 3-week fenofibrate treatment in patients with metabolic syndrome. Fenofibrate 84-95 C-reactive protein Homo sapiens 0-3 18285551-0 2008 Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Fenofibrate 102-113 C-reactive protein Homo sapiens 22-40 18285551-0 2008 Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Fenofibrate 102-113 C-reactive protein Homo sapiens 42-45 18285551-5 2008 Moreover, among subjects with the metabolic syndrome, fenofibrate induced the greatest reduction in CRP levels for TT subjects of the i178T>A compared with TA and AA subjects (-30 for TT, -19 for TA, and -11% for AA; P = 0.004). Fenofibrate 54-65 C-reactive protein Homo sapiens 100-103 18285551-7 2008 CONCLUSIONS: Our results demonstrate that common genetic variants within the CRP gene affect baseline CRP levels and further modulate CRP response in subjects with the metabolic syndrome treated with fenofibrate. Fenofibrate 200-211 C-reactive protein Homo sapiens 77-80 18285551-7 2008 CONCLUSIONS: Our results demonstrate that common genetic variants within the CRP gene affect baseline CRP levels and further modulate CRP response in subjects with the metabolic syndrome treated with fenofibrate. Fenofibrate 200-211 C-reactive protein Homo sapiens 102-105 18285551-7 2008 CONCLUSIONS: Our results demonstrate that common genetic variants within the CRP gene affect baseline CRP levels and further modulate CRP response in subjects with the metabolic syndrome treated with fenofibrate. Fenofibrate 200-211 C-reactive protein Homo sapiens 102-105 21276586-5 2011 Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels. Fenofibrate 16-27 C-reactive protein Homo sapiens 298-316 21117970-7 2011 TG and high-sensitivity C-reactive protein had greater reductions in the fenofibrate and fenofibrate plus ezetimibe groups than the ezetimibe alone group (P <= 0.05 for both) CONCLUSIONS: In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome. Fenofibrate 73-84 C-reactive protein Homo sapiens 24-42 21117970-7 2011 TG and high-sensitivity C-reactive protein had greater reductions in the fenofibrate and fenofibrate plus ezetimibe groups than the ezetimibe alone group (P <= 0.05 for both) CONCLUSIONS: In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome. Fenofibrate 89-100 C-reactive protein Homo sapiens 24-42 21117970-7 2011 TG and high-sensitivity C-reactive protein had greater reductions in the fenofibrate and fenofibrate plus ezetimibe groups than the ezetimibe alone group (P <= 0.05 for both) CONCLUSIONS: In this analysis of patients with mixed dyslipidemia, the lipid effects of ezetimibe plus fenofibrate were generally similar in metabolic syndrome patients versus those without metabolic syndrome. Fenofibrate 89-100 C-reactive protein Homo sapiens 24-42 20143119-8 2010 Significant correlation was observed between VAS and CRP in the fenofibrate group (p < 0.05). Fenofibrate 64-75 C-reactive protein Homo sapiens 53-56 17522372-8 2007 In conclusion, after 12 wk, micronized fenofibrate therapy significantly decreased 3 inflammatory markers (hs-CRP, ESR, and fibrinogen) and improved the lipid profile by decreasing serum triglyceride, cholesterol, and non-HDL-cholesterol levels and increasing HDL-cholesterol; however, it did not change serum proinsulin level, a pancreatic stress marker. Fenofibrate 39-50 C-reactive protein Homo sapiens 110-113 16810076-0 2006 Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients. Fenofibrate 11-22 C-reactive protein Homo sapiens 26-44 17209672-3 2007 Fenofibrate also has nonlipid (i.e. pleiotropic) effects (e.g. it reduces fibrinogen, C-reactive protein and uric acid levels and improves flow-mediated dilatation). Fenofibrate 0-11 C-reactive protein Homo sapiens 86-104 16990410-4 2006 RESULTS: Patients receiving micronized fenofibrate for 24 months in addition to antihypertensive treatment had decreased concentrations of total cholesterol, LDL-cholesterol, triglyceride, apolipoprotein B100, oxidized LDL, high-sensitivity C-reactive protein, P-selectin, and cytokines. Fenofibrate 39-50 C-reactive protein Homo sapiens 241-259 16810076-1 2006 We investigated the effects of fenofibrate on C-reactive protein (CRP) levels in patients with hypertriglyceridemia. Fenofibrate 31-42 C-reactive protein Homo sapiens 46-64 16810076-1 2006 We investigated the effects of fenofibrate on C-reactive protein (CRP) levels in patients with hypertriglyceridemia. Fenofibrate 31-42 C-reactive protein Homo sapiens 66-69 16810076-8 2006 In patients with baseline CRP levels of >or=3 mg/dL, CRP levels were decreased in both the fenofibrate and control groups (P = 0.026 and 0.008, respectively). Fenofibrate 94-105 C-reactive protein Homo sapiens 26-29 16810076-8 2006 In patients with baseline CRP levels of >or=3 mg/dL, CRP levels were decreased in both the fenofibrate and control groups (P = 0.026 and 0.008, respectively). Fenofibrate 94-105 C-reactive protein Homo sapiens 56-59 16875159-7 2006 The micronized fenofibrate caused a significant decrease in serum total cholesterol (by 15%), TG (by 38%), CRP (by 35%), fibrinogen (by 26%) and TBARS (by 33%) concentrations associated with a increase in CAT (by 35%), GSH-Px (by 63%), SOD (by 31%) activities. Fenofibrate 15-26 C-reactive protein Homo sapiens 107-110 16092057-14 2005 C-reactive protein was significantly reduced in all treatment groups, with the atorvastatin and combination groups having the greatest reduction (65% and 68%, respectively, P < .01 vs the fenofibrate group, 44%). Fenofibrate 191-202 C-reactive protein Homo sapiens 0-18 16092057-18 2005 Atorvastatin and combination treatment were more effective than fenofibrate alone in reducing CRP levels. Fenofibrate 64-75 C-reactive protein Homo sapiens 94-97 15543343-14 2004 Both cerivastatin and fenofibrate reduced CRP levels, the decrease being significantly greater after cerivastatin. Fenofibrate 22-33 C-reactive protein Homo sapiens 42-45 15467191-0 2004 C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Fenofibrate 85-96 C-reactive protein Homo sapiens 0-18 15467191-9 2004 In conclusion, our data provide evidence to support the direct pro-inflammatory effects of CRP via CD40-CD40L signaling pathway involved in the pathogenesis of atherosclerosis, and lovastatin and fenofibrate possess anti-inflammatory effects independent of their lipid-lowering action. Fenofibrate 196-207 C-reactive protein Homo sapiens 91-94 15554350-0 2004 The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients. Fenofibrate 14-25 C-reactive protein Homo sapiens 60-78 15554350-3 2004 Our objective was to evaluate the effect of fenofibrate on the levels of high-sensitivity C-reactive protein in dyslipidemic obese patients. Fenofibrate 44-55 C-reactive protein Homo sapiens 90-108 15554350-9 2004 Levels of high-sensitivity C-reactive protein decreased significantly (approximately 74.1%) after fenofibrate treatment from a mean of 0.58+/-0.3 mg/dL to 0.15+/-0.2 mg/dL, P < 0.01. Fenofibrate 98-109 C-reactive protein Homo sapiens 27-45 14612213-5 2003 Both fenofibrate and simvastatin markedly reduced plasma levels of high-sensitivity CRP, IL-1 beta, and sCD40L, and improved endothelium-dependent FMD without mutual differences. Fenofibrate 5-16 C-reactive protein Homo sapiens 84-87 15853856-0 2005 The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients. Fenofibrate 14-25 C-reactive protein Homo sapiens 60-78 14764586-7 2004 A similar global effect of fenofibrate on acute phase protein expression is observed in hyperlipidemic patients chronically treated with fenofibrate, which displayed decreased plasma concentrations of the positive APR proteins fibrinogen, C-reactive protein, serum amyloid A, plasminogen, and alpha2-macroglobulin and increased plasma concentrations of the negative APR albumin, underlining the clinical significance of our findings. Fenofibrate 27-38 C-reactive protein Homo sapiens 239-257 14764586-7 2004 A similar global effect of fenofibrate on acute phase protein expression is observed in hyperlipidemic patients chronically treated with fenofibrate, which displayed decreased plasma concentrations of the positive APR proteins fibrinogen, C-reactive protein, serum amyloid A, plasminogen, and alpha2-macroglobulin and increased plasma concentrations of the negative APR albumin, underlining the clinical significance of our findings. Fenofibrate 137-148 C-reactive protein Homo sapiens 239-257 11382718-9 2001 CONCLUSIONS: These results further strengthen the role of CRP in the pathogenesis of vascular inflammation and, likely, atherosclerosis and provide a crucial insight into a novel mechanism of action of anti-atherosclerosis drugs such as simvastatin and fenofibrate. Fenofibrate 253-264 C-reactive protein Homo sapiens 58-61